Schain, Martin
Johansson, Edvin
Laitinen, Iina
Frödén Löwenmark, Anna
Lubberink, Mark
Gummesson, Anders
Danfors, Torsten
Nuutila, Pirjo
Esterline, Russell
Johansson, Lars
Oscarsson, Jan
Heurling, Kerstin
Article History
Received: 23 October 2024
Accepted: 28 January 2025
First Online: 11 April 2025
Acknowledgements
: The authors acknowledge B. MacIntosh (University of Toronto) for helpful discussions on ASL.
: The datasets generated and analysed in the current study are available from the corresponding author upon reasonable request.
: Antaros Medical funded the study with financial sponsorship from AstraZeneca.
: MS, EJ, IL, AFL, LJ and KH are employed by Antaros Medical. JO and RE are employed by AstraZeneca. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: MS and IL were involved in conduct, analysis and interpretation. EJ, ML, AG, TD, PN, RE, LJ, JO and KH were involved in the conception, design and conduct of the study and the analysis and interpretation of the results. AFL was involved in conception, design and conduct of the study. MS wrote the first draft of the manuscript and all authors edited, reviewed and approved the final version. MS is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the analyses.